Research & Education
CURE Expert Connections
CURE Speaking Out
Email Sign Up
To start your customized experience click the start button
Customize your homepage by selecting specific cancer types.
See all >
Acute Myeloid Leukemia
Cancer of Unknown Primary
Diet and Exercise
Gastrointestinal stromal tumor
General Financial Topics
General Psychosocial Aspect Topics
Head & Neck Cancer
Mantle Cell Lymphoma
Metastatic Breast Cancer
Side Effect Management
Small Lymphocytic Lymphoma (SLL)
Advocacy & Research
Share Your Story
Newsletter Sign Up
See all >
AWARD PROGRAM: Extraordinary Healer
AWARD PROGRAM: Ovarian Cancer Heroes
EDUCATED PATIENT SUMMIT: Lung Cancer
AWARD PROGRAM: Lung Cancer Heroes
Ovarian Cancer Heroes
Bone Health Champions
Terms & Conditions
Cure Media Group, LLC.
2 Clarke Drive
Cranbury, NJ 08512
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
How COVID-19 Affects Patients with Cancer
Researchers from China examined the impact that coronavirus has on patients who are receiving anti-cancer treatment.
Upfront Immunotherapy Options in Patients with Advanced Small Cell Lung Cancer
Combining immunotherapies with chemotherapy has shown improved survival in patients with extensive-stage small cell lung cancer.
Eyes On New Treatments Beyond Chemotherapy in Diffuse Large B-cell Lymphoma
Patients with relapsed and resistant diffuse large B-cell lymphoma can look to new treatments beyond tried-and-true chemotherapy.
Keytruda Plus Chemoradiation Shows Promise in Locally Advanced NSCLC
The combination of Keytruda plus chemoradiotherapy induced a ‘promising’ 12-month progression-free survival rate in patients with locally advanced non-small cell lung cancer.
The Future of Immunotherapy in Bladder Cancer
Treatment for patients with bladder cancer is moving away from VEGF-targeted therapies toward immune checkpoint inhibition, according to one expert.
The Use of Immunotherapy in Blood Cancer Treatment
Kristie L. Kahl and Lee Greenberger
Lee Greenberger, chief scientific officer at the Leukemia and Lymphoma Society, discusses the use of immunotherapy in blood cancer treatment.
Decision-Making Surrounding the Treatment of cSCC
Perspectives on treatment decision-making in cutaneous squamous cell carcinoma, particularly regarding who is involved in selecting therapy.
Experience With Immunotherapy in cSCC
Dr. Todd Schlesinger shares his experience with cemiplimab, an immunotherapy agent used to treat cutaneous squamous cell carcinoma.
Cutaneous Squamous Cell Carcinoma: What Is Immunotherapy?
Considerations for the use of immunotherapy, a novel approach to treatment, in patients with cutaneous squamous cell carcinoma.
$29 Million Awards by the V Foundation in 2019; All-Time Grant Total More Than $250 Million
Top Translational Grants Named for Former CEO Nick Valvano, Former Scientific Advisory Committee Chair Dr. Robert Bast.
Not a member?
Sign up now!
Continue without login